

For the prevention of chemotherapy-induced and radiation-induced nausea and vomiting (CINV/RINV)

Kytril helps keep emesis from invading their lives

...With the confidence of more than 8 years experience

Clinical Features

- 2-mg single oral dose provides efficacy equal to 32-mg Zofran[®]* IV in CINV^{1,2}
- Not associated with QT_c prolongation^{3,4}
- The **only** 5-HT₃ receptor antagonist not metabolized through the CYP2D6 pathway⁵

The most frequently reported clinical adverse events occurring in ≥5% of patients receiving Kytril were headache, constipation, asthenia, diarrhea, abdominal pain,[†] dyspepsia,[†] pain,[‡] anemia,[‡] fever[‡] and elevated hepatic enzymes.[‡] The use of Kytril in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask progressive ileus and/or gastric distention.

*Zofran (ondansetron HCl) is a registered trademark of The GlaxoSmithKline Group of Companies.


[†]Associated with Kytril Tablets only.

[‡]Associated with Kytril Injection for postoperative nausea and vomiting only.



KYTRIL[®]
granisetron HCl
Tablets, Oral Solution & IV

Helping patients feel better



Please see summary of product information on adjacent page.

References:

1. Gralla RJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. *J Clin Oncol.* 1998;16:1568-1573.
2. Perez EA et al. Comparison of single-dose oral granisetron versus IV ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. *J Clin Oncol.* 1998;16:754-760.
3. Keefe DL. The cardiotoxic potential of the 5-HT₃ receptor antagonist antiemetics; is there cause for concern? *Oncologist.* 2002;7:65-72.
4. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. *Eur J Cancer.* 2003;39:927-931.
5. Bloomer JC et al. Characterisation of the cytochrome P450 enzymes involved in the *in vitro* metabolism of granisetron. *Br J Clin Pharmacol.* 1994;38:557-566.

Roche

Pharmaceuticals

Please visit www.kytril.com
Copyright © 2004 by Roche Laboratories Inc.
All rights reserved.

Roche Laboratories Inc.
340 Kingsland Street
Nutley, New Jersey 07110-1199
www.rocheusa.com